Ecstasy (MDMA) Rapid Test

MDMA, commonly known as ecstasy, is a synthetic stimulant-type substance associated with recreational misuse and drug-of-abuse screening. The term ecstasy may also be used broadly for tablets or products that can contain other substances. The Ecstasy MDMA Rapid Test is not intended to diagnose intoxication, addiction, or any medical condition by itself. It is a preliminary urine screening tool that helps detect possible MDMA exposure according to the stated cut-off level.

• The MDMA urine rapid test is designed to detect MDMA-related substances in urine. A urine specimen is applied to the test device, and the result is read according to the product insert.
• The 500ng/ml cut-off means the test is designed to provide a qualitative screening result at or above the specified detection threshold.
• A positive screening result should be considered preliminary. Where results are used for medical, employment, legal, rehabilitation, or institutional decisions, confirmatory laboratory testing may be required according to local regulations and testing policy.

• Urine is widely used in drug of abuse screening because it is practical, non-invasive, and suitable for detecting drug exposure after metabolism and excretion.
• For professional screening programs, urine-based Ecstasy MDMA rapid test kits are useful because they support quick workflow, scalable testing, and simple result interpretation.
• This makes the test suitable for international diagnostic portfolios, rehabilitation support programs, institutional testing, and occupational health screening workflows.

The LARKSOIS Pharma Ecstasy MDMA Rapid Test 500ng/ml may be used in professional diagnostic and institutional screening environments.

Applications

• Drug of abuse screening programs
• Clinical toxicology laboratories
• Hospitals and clinics
• Workplace drug screening programs
• Rehabilitation and recovery centers
• Forensic screening units
• Institutional drug monitoring workflows
• International diagnostic product distribution

Instructions

• Urine-based rapid test format
• 500ng/ml MDMA cut-off
• Designed for ecstasy / MDMA drug screening
• Easy-to-read qualitative result
• Suitable for professional testing environments
• Supports fast preliminary screening
• Useful for laboratories, institutions, and occupational health programs
• International B2B product suitability under LARKSOIS Pharma

The Ecstasy (MDMA) Rapid Test uses a rapid urine screening method for qualitative detection of MDMA-related substances. It is designed to provide a preliminary screening result at the stated 500ng/ml cut-off.

Benefits

• Urine-based rapid screening format
• 500ng/ml MDMA cut-off
• Designed for ecstasy / MDMA screening
• Suitable for professional diagnostic use
• Supports fast preliminary results
• Useful for toxicology and compliance workflows
• Applicable for laboratories, clinics, and institutions
• Supports international drug screening requirements

The Ecstasy (MDMA) Rapid Test is designed for urine specimens. Urine is widely used in drug screening because it is practical for detecting drug exposure in professional screening workflows.

Guidance

• Use urine specimens only
• Use clean sample collection procedures
• Follow the product insert carefully
• Treat all urine samples as potentially biohazardous
• Interpret results within the stated reading window
• Use confirmatory testing where required by clinical, legal, workplace, or institutional policy

Note

A rapid screening result should be considered preliminary unless confirmed by a validated laboratory method where required.

The Ecstasy (MDMA) Rapid Test by LARKSOIS Pharma has a stated cut-off of 500ng/ml. This means the test is designed to screen for MDMA-related substances in urine at or above the validated threshold. LARKSOIS Pharma should mention the exact performance details according to the final product insert, technical file, and regulatory documentation.

• The MDMA rapid urine test plays an important role in drug-of-abuse screening because MDMA misuse can create health, safety, workplace, and legal concerns.
• In professional testing programs, rapid screening helps identify samples that may require further laboratory evaluation.
• For global buyers, the Ecstasy MDMA Rapid Test 500ng/ml is an important product for diagnostic portfolios, drug testing panels, rehabilitation support, workplace safety programs, and forensic screening applications.

Steps

• Bring the test device and urine specimen to the recommended testing condition
• Open the sealed pouch only when ready to test
• Collect urine using a clean sample collection procedure
• Apply the urine specimen according to the product insert
• Wait for the test reaction to complete within the instructed time
• Read the result within the approved interpretation window
• Dispose of used materials according to laboratory safety rules

Note

The exact procedure must follow the official LARKSOIS Pharma product insert supplied with the Ecstasy (MDMA) Rapid Test.

Positive

A positive result suggests that MDMA-related substances may be present in the urine specimen at or above the stated cut-off. Positive results are preliminary unless confirmed by an appropriate laboratory method.

Negative

A negative result suggests that MDMA-related substances were not detected or were below the test cut-off at the time of testing. A negative result does not replace clinical or professional judgment.

Invalid

If the control indicator does not appear, the result is invalid. The test should be repeated with a new device and fresh urine specimen according to the product insert.

Instructions

• Store in a cool and dry place
• Keep away from direct sunlight
• Do not freeze the test kit
• Keep sealed until use
• Avoid moisture exposure
• Do not use after expiry date
• Keep away from children and unauthorized handling

Instructions

• For professional screening use only
• Use only the recommended specimen type: urine
• Do not use damaged, opened, or expired test kits
• Read the product insert before testing
• Follow local regulatory and workplace testing guidelines
• Do not interpret results after the recommended reading time
• Positive screening results should be confirmed using an approved laboratory method
• Test results should be interpreted with clinical, legal, occupational, or institutional context

LARKSOIS Pharma focuses on reliable pharmaceutical and diagnostic products for international healthcare markets. The Ecstasy MDMA Rapid Test 500ng/ml is designed for buyers looking for urine-based drug of abuse screening solutions.

Advantages

• 500ng/ml MDMA cut-off
• Urine specimen compatibility
• Rapid screening format
• Suitable for professional diagnostic programs
• Useful for workplace and institutional testing
• Supports preliminary MDMA screening workflows
• International product positioning under LARKSOIS Pharma